Federal Register / Vol. 74, No. 64 / Monday, April 6, 2009 / Notices 15499 

questions, as well as any responses to 

the questions themselves based on 

information that may already be in the 

public domain. The EMA Workgroup 

further requests comment on the utility 

of the working definition of EMA used 

here. A transcript of the public meeting 

will be made available. 

Please note that FDA does not wish to 

publicize sensitive information that 

could potentially be used by those who 

wish to commit EMA or other 

adulteration or that identifies those who 

may be committing adulteration FDA 

would like to remind the public that if 

they have information about these or 

any other problems they have 

encountered with FDA products, they 

may report such information at http:// 

www.fda.gov/opacom/backgrounders/ 

problem.html. In addition, if the public 

has information pertaining to suspected 

criminal activity with regard to FDAregulated products (e.g., information 

about individuals who may be 

committing EMA or other adulteration), 

they may contact FDA’s Office of 

Criminal Investigations at http:// 

www.fda.gov/oci/default.htm in lieu of 

responding publicly to this document. 

(1) General Questions: 

a. What information should U.S. 

regulators seek and from what 

sources to help predict and prevent 

EMA? What further steps can U.S. 

regulators take to predict and 

prevent EMA? 

b. What are members of industry 

doing to prevent EMA? What 

further steps can industry take to 

prevent EMA? 

c. What recent examples of known 

or suspected EMA domestically and 

internationally should U.S. 

regulators study and learn from? 

d. What information do other 

organizations (including, but not 

limited to, trade organizations and 

security service providers) have that 

would be useful in predicting and 

preventing EMA? What are 

members of other organizations 

doing to prevent EMA? 

e. What are other government 

regulators within and outside of the 

United States doing to predict and 

address EMA? 

f. What indicators (economic-based, 

chemistry-based, etc.) might be 

used to detect potential EMA? 

(2) Questions pertaining to attributes of 

products, components/ingredients that 

may be at risk for EMA: 

a. What are attributes of products or 

components/ingredients of products 

that may cause them to be more 

vulnerable to EMA? 

b. What food products are marketed 

based on measured content of 

certain constituents, such as 

content of certain proteins, certain 

fats, or certain sugars? 

(3) Questions pertaining to changes in 

the marketing environment: What 

changes relevant to the risk for EMA 

have occurred recently in: 

a. The marketing environment of 

products or components/ 

ingredients? 

b. The sourcing and/or distribution 

of products? 

c. The prices, output, imports or 

exports of products or components/ 

ingredients? 

d. The supply of components/ 

ingredients or source materials for 

products? 

(4) Questions about detection methods: 

a. What analytical equipment or 

methods currently used by industry 

and regulators to establish the 

identity or quality of a product or 

its conformity to specifications may 

be inadequate to detect evidence of 

EMA or adulterated products or 

ingredients? 

b. Are there appropriate analytical 

methods/equipment that could be 

used instead of, or in addition to, 

existing methods or equipment in 

particular situations? 

c. What rapid methods can be used 

to detect adulteration of products or 

ingredients? 

(5) What systems are currently being 

used to track and verify components/ 

ingredients from their source? 

(6) Are there particular types of industry 

structures or supply chains that are 

especially vulnerable to or secure from 

potential EMA? 

IV. Transcripts 

Please be advised that as soon as a 

transcript is available, it will be 

accessible at http:// 

www.regulations.gov. It may be viewed 

at the Division of Dockets Management 

(HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD. A transcript will 

also be available in either hardcopy or 

on CD-ROM, after submission of a 

Freedom of Information request. Written 

requests are to be sent to Division of 

Freedom of Information (HFI–35), Office 

of Management Programs, Food and 

Drug Administration, 5600 Fishers 

Lane, rm. 6–30, Rockville, MD 20857. 

V. Comments 

Interested persons may submit to the 

Division of Dockets Management (see 

ADDRESSES) written or electronic 

comments regarding this document. 

Submit a single copy of electronic 

comments or two paper copies of any 

mailed comments, except that 

individuals may submit one paper copy. 

Comments are to be identified with the 

docket number found in brackets in the 

heading of this document. Received 

comments may be seen in the Division 

of Dockets Management between 9 a.m. 

and 4 p.m., Monday through Friday. 

Dated: April 1, 2009. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E9–7843 Filed 4–2–09; 4:15 pm] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases 

Diabetes Mellitus Interagency 

Coordinating Committee; Notice of 

Meeting 

The Diabetes Mellitus Interagency 

Coordinating Committee (DMICC) will 

hold a meeting on May 6, 2009, from 

12:30 to 4:30 p.m. at Building 31C, 

Conference Room 6C, on the NIH 

campus, 9000 Wisconsin Ave., 

Bethesda, MD. The meeting will be open 

to the public, with attendance limited to 

space available. Non-federal individuals 

planning to attend the meeting should 

notify the Contact Person listed on this 

notice at least 2 days prior to the 

meeting. Individuals who plan to attend 

and need special assistance, such as 

sign language interpretation or other 

reasonable accommodations, should 

inform the Contact Person listed below 

at least 10 days in advance of the 

meeting. 

The DMICC facilitates cooperation, 

communication, and collaboration on 

diabetes among government entities. 

DMICC meetings, held several times a 

year, provide an opportunity for 

members to learn about and discuss 

current and future diabetes programs in 

DMICC member organizations and to 

identify opportunities for collaboration. 

The May 6, 2009, DMICC meeting will 

discuss ‘‘Federally Supported DiabetesRelated National Education Programs.’’ 

Any member of the public interested 

in presenting oral comments to the 

Committee should notify the Contact 

Person listed on this notice at least 10 

days in advance of the meeting. 

Interested individuals and 

representatives or organizations should 

submit a letter of intent, a brief 

description of the organization 

represented, and a written copy of their 

oral presentation in advance of the 

meeting. Only one representative of an 

organization will be allowed to present 


pwalker on PROD1PC71 with NOTICES
15500 Federal Register / Vol. 74, No. 64 / Monday, April 6, 2009 / Notices 

oral comments and presentations will be 

limited to a maximum of five minutes. 

Both printed and electronic copies are 

requested for the record. In addition, 

any interested person may file written 

comments with the Committee by 

forwarding their statement to the 

Contact Person listed on this notice. The 

statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Because of time constraints for the 

meeting, oral comments will be allowed 

on a first come, first served basis. 

Please Note: The NIH has instituted 

security measures to ensure the safety of NIH 

employees and property. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport). All visitors should be prepared 

to have their personal belongings inspected 

and to go through metal detection inspection. 

Visitors are strongly encouraged to take 

public transportation to the NIH campus, as 

there are very few visitor parking spaces 

available. NIH Building 31C is a 10-minute 

walk from the Medical Center Station on the 

Red Line of the Metro. 

A registration link and information 

about the DMICC meeting will be 

available on the DMICC Web site: 

http://www.diabetescommittee.gov. 

Members of the public who would like 

to receive e-mail notification about 

future DMICC meetings could register 

on a listserv available on the same Web 

site. 

For further information concerning 

this meeting, contact Dr. Sanford 

Garfield, Executive Secretary of the 

Diabetes Mellitus Interagency 

Coordinating Committee, National 

Institute of Diabetes and Digestive and 

Kidney Diseases, 6707 Democracy 

Boulevard, Room 654, MSC 5460, 

Bethesda, MD 20892–5460, Telephone: 

301–594–8803, fax: 301–402–6271, 

E-mail: dmicc@mail.nih.gov. 

Dated: April 1, 2009. 

Sanford Garfield, PhD, 

Executive Secretary, DMICC, Division of 

Diabetes, Endocrinology and Metabolic 

Diseases, NIDDK, National Institutes of 

Health. 

[FR Doc. E9–7724 Filed 4–3–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel Clinical Sciences. 

Date: June 22–23, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Laurie Friedman Donze, 

PhD, Scientific Review Officer, Office of 

Scientific Review, National Center for 

Complementary, and Alternative Medicine, 

NIH, 6707 Democracy Blvd., Suite 401, 

Bethesda, MD 20892, 301–402–1030, 

donzel@mail.nih.gov. 

Dated: March 31, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–7709 Filed 4–3–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel Loan Repayment 

Program. 

Date: April 28, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, One 

Democracy Plaza, 6701 Democracy 

Boulevard, Bethesda, MD 20892. (Telephone 

Conference Call) 

Contact Person: Laurie Friedman Donze, 

PhD, Scientific Review Officer, Office of 

Scientific Review, National Center for 

Complementary, and Alternative Medicine, 

NIH, 6707 Democracy Blvd., Suite 401, 

Bethesda, MD 20892, 301–402–1030, 

donzel@mail.nih.gov. 

Dated: March 31, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–7713 Filed 4–3–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Notice of Meeting 

Pursuant to Section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the National Advisory 

Council for Complementary and 

Alternative Medicine (NACCAM) 

meeting. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussion could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 


pwalker on PROD1PC71 with NOTICES